News & Updates

Treatment with the oral Toll-like receptor 8 (TLR8) agonist selgantolimod once weekly for 24 weeks is well tolerated and generally safe in patients with chronic hepatitis B (CHB) under viral suppression, according to a recent study.

Early treatment with a single dose of pegylated recombinant IL-29 type III interferon (IFN), otherwise known as peg lambda, significantly reduced clinical events in the phase III TOGETHER study evaluating mostly vaccinated, acutely symptomatic COVID-19 outpatients.

For patients with Hodgkin’s lymphoma who have completed a first-line chemotherapy regimen that includes doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD), neutrophil and lymphocyte counts are predictive of disease prognosis, as reported in a study from Singapore.

In the extended follow up of the phase III CheckMate 274 trial, nivolumab continued to show benefit for patients with muscle-invasive urothelial carcinoma (MIUC; bladder, ureter, or renal pelvis) who were at high risk for recurrence following bladder resection.

In the treatment of polycystic ovary syndrome (PCOS), the combination of metformin plus oral contraceptives appears to benefit women without obesity, inducing favourable effects on glucose metabolism with no further harm on lipid metabolism, according to the results of a meta-analysis.

Combination therapy using yttrium 90 (Y90) radioembolization and sorafenib/nivolumab for patients with hepatocellular carcinoma (HCC), with hepatic vein (HV) or inferior vena cava (IVC) invasion, results in better outcomes, as indicated by increased response rates, overall survival (OS), and progression-free survival (PFS) benefits, a study has found.